224 related articles for article (PubMed ID: 26277659)
1. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.
Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ
J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
4. Improved tumor targetability of Tat-conjugated PAMAM dendrimers as a novel nanosized anti-tumor drug carrier.
Yan C; Gu J; Hou D; Jing H; Wang J; Guo Y; Katsumi H; Sakane T; Yamamoto A
Drug Dev Ind Pharm; 2015 Apr; 41(4):617-22. PubMed ID: 24564798
[TBL] [Abstract][Full Text] [Related]
5. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.
Liu Y; Ng Y; Toh MR; Chiu GNC
J Control Release; 2015 Dec; 220(Pt A):438-446. PubMed ID: 26551345
[TBL] [Abstract][Full Text] [Related]
6. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.
Mi Y; Zhao J; Feng SS
J Control Release; 2013 Aug; 169(3):185-92. PubMed ID: 23403395
[TBL] [Abstract][Full Text] [Related]
7. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
8. Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery.
Zhang Y; Zhang P; Zhu T
Biomed Pharmacother; 2019 Jan; 109():475-483. PubMed ID: 30399584
[TBL] [Abstract][Full Text] [Related]
9. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
Qi X; Fan Y; He H; Wu Z
Carbohydr Polym; 2015 Aug; 126():231-9. PubMed ID: 25933544
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab.
Ma P; Zhang X; Ni L; Li J; Zhang F; Wang Z; Lian S; Sun K
Int J Nanomedicine; 2015; 10():2173-90. PubMed ID: 25834432
[TBL] [Abstract][Full Text] [Related]
12. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
[TBL] [Abstract][Full Text] [Related]
13. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
15. Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells.
Otis JB; Zong H; Kotylar A; Yin A; Bhattacharjee S; Wang H; Baker JR; Wang SH
Oncotarget; 2016 Jun; 7(24):36002-36013. PubMed ID: 27144519
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer.
Oddone N; Lecot N; Fernández M; Rodriguez-Haralambides A; Cabral P; Cerecetto H; Benech JC
J Nanobiotechnology; 2016 Jun; 14(1):45. PubMed ID: 27297021
[TBL] [Abstract][Full Text] [Related]
17. Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.
Liu J; Liu J; Chu L; Wang Y; Duan Y; Feng L; Yang C; Wang L; Kong D
Int J Nanomedicine; 2010 Dec; 6():59-69. PubMed ID: 21289982
[TBL] [Abstract][Full Text] [Related]
18. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
19. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
